New: NCI-funded clinical trial search
Mednet Logo
CommunityEndocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

Is the newly approved oral PCSK9 Inhibitor, Lipfendra, as clinically efficacious as injectable versions of the drug such as Repatha?

1
3 Answers

Mednet MemberInvited Expert
Endocrinology · Medical University of South Carolina College of Medicine

While this new cholesterol-lowering agent, enlicitdie, has been shown to be very effective, we cannot say it is "as efficacious" as PCSK9 monoclonal antibodies. The studies were done in different populations, with different baseline LDL levels, different potential concomitant medications, etc. The o...

How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?

1 Answers

Mednet MemberInvited Expert
Nephrology · UAB Medicine

The ESPRIT trial largely validates findings from SPRINT in a Chinese population. One major difference is that 38% of ESPRIT participants had diabetes mellitus (DM). A reduction in death from a CV cause drove the significance in the primary outcome (similar to SPRINT), and BP was measured 3x after a ...

Is the combination of SGLT2i and GLP 1 R agonist therapy contraindicated in patients who develop an episode of euglycemic DKA?

1 Answers

Mednet MemberInvited Expert
Endocrinology · Yale School of Medicine

Therapy always needs to be individualized, but in most cases, SGLT2 inhibitors should be stopped in patients who have had euglycemic DKA. Such individuals likely have low endogenous insulin production. GLP1R agonists could further increase the risk of recurrent euglycemic DKA, and I agree with Mehta...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?

1
1 Answers

Mednet MemberInvited Expert
Endocrinology · Boston University School of Medicine

Hyperparathyroidism does increase the risk of developing kidney stones. A study in New England Journal of Medicine, Broadus et al., PMID 7351950, reported that patients with elevated concentrations of 1,25-dihydroxyvitamin D are at increased risk for kidney stones. The reason is that 1,25-dihydroxyv...

Which osteoporosis medications are safe to offer a patient with severe osteoporosis who is strictly vegan?

1 Answers

Mednet MemberInvited Expert
Endocrinology · Boston University School of Medicine

It would be helpful to know what severe osteoporosis means and what the T-scores are in the hip and spine. For patients who are strictly vegan, I would put them on an appropriate osteoporotic medication, making sure that they have an adequate calcium intake either from their diet or supplements, alo...

Would you consider reducing physiological replacement doses of steroids for secondary adrenal insufficiency in patients who develop steroid induced complications such as avascular necrosis of the joints?

1 Answers

Mednet MemberInvited Expert
Endocrinology · Johns Hopkins Endocrinology and Pituitary Center

That depends on what you mean by "physiological replacement dose". I usually tell patients to use the lowest dose that keeps them feeling well, and sometimes they are able to reduce the dose on less stressful days, such as weekends. Most patients function well with less than 20 mg of hydrocortisone ...

How would you empirically manage a large sellar/suprasellar mass with encasement of the right cavernous and terminal internal carotid arteries?

2
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Arizona

Knowing the histology of the mass would really help in creating more accurate treatment recommendations. A biopsy of a sellar mass is usually accomplished by an endonasal-endoscopic transsphenoidal approach utilizing the expertise of an ENT surgeon and a skull-base neurosurgeon. However, in this cas...

In an obese male with low testosterone, would you initiate testosterone replacement therapy at the initial visit, or start tirzepatide first and monitor for improvement in testosterone levels and erectile function?

2 Answers

Mednet MemberInvited Expert
Endocrinology · Endocrine Care Center At Uw Medical Center Roosevelt

Dr. @Dr. First Last has given a thoughtful answer. Assuming no evidence of a structural hypothalamic-pituitary-testicular (HPT) disease (normal prolactin, LH, and FSH in the low-normal to normal range, normal free T4), the best approach is weight loss for these men. Whether to try lifestyle changes ...

How would you define failure of anabolic therapy for severe osteoporosis and when would you consider ordering a second round of Evenity or PTH analogue therapy?

2 Answers

Mednet MemberInvited Expert
Rheumatology · U of AZ Phoenix Dept of Orthopaedics

“Failure” of any therapy is often in the eyes of the beholder. The most efficient way to determine if there is anabolic activity is to measure a serum PINP (does not need fasting) and, for the PTH anabolic recheck, the PINP 2-3 months later. IF the delta is &gt;10, you can be confident there is more pr...

In patients with osteoporosis at high fracture risk, what factors most influence your decision to prescribe teriparatide versus abaloparatide?

3 Answers

Mednet MemberInvited Expert
Rheumatology · Icahn School of Medicine at Mount Sinai

Both abaloparatide and teriparatide are very effective anabolic agents to reduce vertebral and nonvertebral fracture risk in patients with osteoporosis (although clinical trials did not demonstrate reduction of hip fracture risk). The two agents are more similar than different and both induce an an...